La cadena de opciones muestra datos clave de las opciones de acciones de Psyence Biomedical a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Psyence Biomedical..

Psyence Biomedical (NASDAQ:PBM) Bolsa, Cadena de Opciones

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

AADI

APTO

CADL

CARA

HUMA

MESO

MOBX

MTEM

NVNI

OCEA

PRFX

QUBT

ZCAR

FedEx sube un 8,7% con resultados sólidos y una nueva estrategia. Descubre otras acciones destacadas en premercado hoy.

Las acciones de FedEx (FDX) suben alrededor de un 9%; 20 acciones que se mueven en premercado

Earnings

Equities

News

Futures

Economics

Federal Reserve

Pre-Market Outlook

Markets

Movers

Trading Ideas

Los futuros caen ante la &#34;Triple Brujería&#34; y nuevos datos de inflación. ¿Qué dicen los analistas sobre el mercado?

Futuros de EE.UU. caen antes de datos clave de inflación y Triple Brujería

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical Ltd

PACIFIC BAY MINERALS LTD by Pacific Bay Minerals Ltd.

Pacific Bay Minerals Ltd

PACIFIC BOOKER MINERALS by Pacific Booker Minerals Inc.

Pacific Booker Minerals Inc

PGIM US Large-Cap Buffer 20 ETF - March

PT BUMI RESOURCES TBK by PT Bumi Resources TBK

PT Bumi Resources Tbk

PT BUMI RESTBK UNSP/ADR by PT Bumi Resources TBK

SHL Telemedicine Ltd PGIM US Large-Cap Buffer 20 ETF - May

<h3>Gainers</h3>
<ul>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) stock moved upwards by 139.4% to $12.02 during Monday's pre-market session. The market value of their outstanding shares is at $36.3 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) stock increased by 86.24% to $3.25. The company's market cap stands at $7.2 million. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares moved upwards by 85.3% to $1.53. The company's market cap stands at $53.4 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock increased by 51.7% to $2.67. The market value of their outstanding shares is at $2.8 million. </li>
<li>Ikena Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) stock rose 23.22% to $1.91. The market value of their outstanding shares is at $92.1 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock moved upwards by 16.63% to $0.7. The market value of their outstanding shares is at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares declined by 25.6% to $0.06 during Monday's pre-market session. The company's market cap stands at $6.6 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock declined by 23.08% to $0.7. The market value of their outstanding shares is at $2.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 18.87% to $2.58. The company's market cap stands at $2.1 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares fell 15.8% to $0.52. The company's market cap stands at $96.2 million. </li>
<li>Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) shares fell 13.42% to $24.01. The market value of their outstanding shares is at $203.0 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares declined by 13.15% to $0.39. The company's market cap stands at $17.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ELMD

GTBP

HCWB

HSDT

IKNA

PHIO

PTIX

RAPT

TNXP

TRAW

12 Health Care Stocks Moving In Monday's Pre-Market Session

WIIM

Psyence Biomedical shares are trading lower after the company announced a $2M private placement.

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) ("Psyence Biomed" or the "Company") today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrant in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant in lieu thereof) and accompanying series A common warrant and short-term series B common warrant in a private placement. The series A common warrants and short-term series B common warrants will have an exercise price of $2.00 per share and will be exercisable immediately upon issuance. The series A common warrants will expire five years from the date of issuance and the short-term series B common warrants will expire two years from the date of issuance. The private placement is expected to close on or about December 24, 2024, subject to the satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
The gross proceeds from the offering are expected to be approximately $2.0 million, prior to deducting placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

Offerings

Psyence Biomed Announces $2M Private Placement

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) ("Psyence Biomed" or the "Company") today announced that it has received notice from the Nasdaq Hearings panel that the Company has regained compliance with all applicable Nasdaq continued listing requirements.
As previously announced, Psyence Biomed requested to be transferred from The Nasdaq Global Market to The Nasdaq Capital Market, effective November 15, 2024. As a result of this transfer, the Company regained compliance with listing rules 5550(a)(5), the $1.0 million minimum market value of publicly held shares requirement, and 5550(b)(1), the $2.5 million minimum stockholders' equity requirement.
Additionally, the Company obtained shareholder approval during its Annual General Meeting on November 12, 2024 to effect a 75-for-1 share consolidation. This share consolidation, which went into effect on November 26, 2024, was intended to address Nasdaq's listing rule 5550(a)(2), the $1 minimum bid price requirement. As the Company's shares have traded above $1 for the subsequent 18 trading days following the share consolidation, the minimum bid price requirement has been formally satisfied.

Government

Regulations

Psyence Biomed Regains Nasdaq Compliance After Share Consolidation

Psyence Biomedical Files Prospectus Relates To Potential Offer, Sale, From Time To Time 10.9M Common Shares By Selling Securityholders

<h3>Gainers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares rose 114.6% to $1.03 during Friday's pre-market session. The company's market cap stands at $3.8 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares increased by 67.34% to $5.79. The market value of their outstanding shares is at $744.9 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares moved upwards by 62.19% to $3.99. The company's market cap stands at $3.3 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares increased by 37.77% to $0.6. The company's market cap stands at $8.3 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares rose 29.25% to $30.75. The market value of their outstanding shares is at $162.2 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 16.55% to $3.45. The market value of their outstanding shares is at $3.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock declined by 53.1% to $0.16 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. </li>
<li>Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) stock decreased by 38.5% to $1.23. The market value of their outstanding shares is at $77.1 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares declined by 32.43% to $0.44. The market value of their outstanding shares is at $2.2 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock decreased by 21.86% to $0.93. The company's market cap stands at $44.9 million. </li>
<li>Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares declined by 20.14% to $82.61. The company's market cap stands at $366.9 billion. </li>
<li>Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) shares decreased by 17.71% to $2.51. The company's market cap stands at $10.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

BCAB

GALT

ISPC

MNPR

QNRX

SSKN

12 Health Care Stocks Moving In Friday's Pre-Market Session

Shares of FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) rose sharply in today's pre-market trading as the company posted stronger-than-expected <a href="https://www.benzinga.com/news/earnings/24/12/42605034/fedex-stock-rallies-on-better-than-expected-q2-eps-freight-spin-off-announcement">results for its second quarter</a>.
The company also announced that it has decided to pursue a full separation of FedEx Freight through the capital markets, creating a new publicly traded company.
FedEx shares jumped 8.7% to $299.80 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) gained 80.5% to $0.3070 in pre-market trading after the company announced it was granted an extension to provide compliance evidence for a continued Nasdaq listing.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) gained 67.4% to $4.12 in pre-market trading fater jumping more than 60% on Thursday. The company announced it has entered into an IP licensing and mutual exclusivity agreement with Optimi Health Corp.</li>
<li>Ocean Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) climbed 62.5% to $0.9576 in pre-market trading.</li>
<li>Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) gained 52.8% to $4.08 in pre-market trading after jumping 317% on Thursday.</li>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) rose 44.5% to $5.00 in pre-market trading as the company announced the FDA approval of SYMVESS&#x2122; (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma.</li>
<li>Aadi Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AADI#NASDAQ">AADI</a>) gained 35.3% to $3.14 in pre-market trading after the company secured $100 million PIPE financing and announced the sale of FYARRO for $100 million.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) gained 26.9% to $1.19 in pre-market trading after the company announced 7.85 million of its shares was acquired by Gilead Sciences.</li>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) rose 17.4% to $8.78 in pre-market trading after dipping over 12% on Thursday.</li>
<li>Clearwater Paper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLW#NYSE">CLW</a>) gained 11.8% to $27.62 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Molecular Templates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares tumbled 49.5% to $0.1785 in pre-market trading after the company announced notice of delisting and failure to satisfy continued listing rules.</li>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) declined 36.4% to $7.10 in pre-market trading after jumping around 410% on Thursday.</li>
<li>Cara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares fell 26.7% to $0.2998 in pre-market trading after jumping 56% on Thursday. Cara Therapeutics recently announced it entered into an all-stock merger with Tvardi Therapeutics.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) fell 25.8% to $76.80 in pre-market trading. Novo Nordisk said CagriSema demonstrated weight loss in adults with obesity or overweight in the REDEFINE 1 trial.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) shares dipped 25.2% to $0.9730 in pre-market trading after climbing 65% on Thursday.</li>
<li>Mobix Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) fell 24.5% to $1.57 in today's pre-market trading after reporting third-quarter results.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) dipped 23.6% to $1.94 in pre-market trading. Zoomcar said it launched Zoomcar Cabs, which are affordable car rentals with drivers as a new offering.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares fell 18.1% to $13.72 in pre-market trading. Mesoblast shares jumped over 36% on Thursday after the company announced the FDA approved Ryoncilas the first mesenchymal stromal cell therapy in the United States.</li>
<li>Candel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) fell 13.1% to $8.66 in pre-market trading after jumping over 52% on Thursday.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) fell 11.1% to $13.46 in pre-market trading after declining 41% on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42609619/sp-500-nasdaq-end-in-red-as-investor-sentiment-declines-micron-tumbles-after-sales-miss-greed-index-in-extreme-fear-zone">S&amp;P 500, Nasdaq End In Red As Investor Sentiment Declines, Micron Tumbles After Sales Miss: Greed Index In &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>

Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

U.S. stock futures declined on Friday, ahead of the &#8220;Triple Witching&#8221; hour, which is expected to see the expiry of about $6.6 trillion options, for the quarter.
This comes after the market fell on Wednesday after the Federal Reserve&#8217;s hawkish cut and ended mixed on Thursday. In Friday&#8217;s premarket, all four major indices were trading lower.
The 10-year and two-year Treasury notes yielded 4.55% and 4.28%, respectively. The probability of having no change in the interest rates for the upcoming Jan. 31, 2025 decision was at 89.3%, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group&#8217;s FedWatch tool.
Investors will receive another critical economic data point on Friday with the release of the November personal consumption expenditures (PCE) inflation index. This release follows other inflation indicators that suggest price increases accelerated in November.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-1.12%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.78%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.57%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.13%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 1.16% to $579.30&nbsp;and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 1.23% to $507.83, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
The S&amp;P 500 ended the day essentially unchanged after giving up earlier gains. The Nasdaq 100 fell 0.5%, fluctuating between small gains and losses throughout the session.
However, Dow Jones ended marginally higher, breaking its 10-day losing streak.
Most sectors on the S&amp;P 500 closed on a negative note, with materials, real estate, and energy stocks recording the biggest losses on Thursday. However, utilities and financials stocks bucked the overall market trend, closing the session higher.
Thursday&#8217;s economic data showed a revision upward in one of the Fed&#8217;s preferred inflation measures to 2.2%.
As Fed Chair Jerome Powell has indicated that further easing would require additional progress on inflation, market participants will now focus on the final significant economic data point of the year: November&#8217;s personal consumption expenditures, due out on Friday.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.10%</td>
<td>19,372.77</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.087%</td>
<td>5,867.08</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.036%</td>
<td>42,342.24</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.45%</td>
<td>2,221.50</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
The &#8220;Triple Witching&#8221; hour is a quarterly event that occurs during the final hour of trade on the third Friday of March, June, September, and December. During this period, contracts for stock index futures, stock index options, and stock options all expire at the same time.
According to the Chairman and Founder of Navellier &amp; Associates, Louis Navellier, &#8220;The timing of buying the dip is complicated by options expiration tomorrow and Christmas next week, but a recovery by the end of the year would not surprise anyone.&#8221;
He also said, &#8220;In my opinion, the stock and bond market reactions to the FOMC Statement, dot plot, and Fed Chairman Powell's press conference were grossly overdone and eviscerated all the stock market gains since the Presidential election.&#8221;
According to him, both France and Germany are in the midst of a political crisis and are "headless" until new leadership emerges. &#8220;As a result, I am expecting up to four Fed rate cuts in 2025 as collapsing interest rates in the eurozone also cause U.S. Treasury yields to decline,&#8221; he said.
However, Tom Lee, managing partner and head of research at Fundstrat Global Advisors, thinks <a href="https://www.benzinga.com/markets/equities/24/12/42608297/tom-lee-explains-why-fewer-cuts-in-2025-could-boost-the-market-urges-investors-to-buy-the-dip-amid-recent-volatility#:~:text=What%20Happened%3A%20%E2%80%9CThe%20fewer%20cuts,on%20Thursday%2C%20according%20to%20Fundstrat.&amp;text=%2C%20suffering%20its%20steepest%20one%2Dday%20decline%20since%20September%202022">fewer cuts are better for the economy</a>.
"The fewer cuts [the Fed does] in 2025, it actually is better for this bull market because it provides a lot of future ammunition to protect the economy," he said.
"I know yesterday's (Wednesday&#8217;s) pullback was really painful, but to us, the fundamentals supporting stocks are intact.&#8221;
Carson Research&#8217;s vice president and global macro strategist, Sonu Varghese called 2024 a &#8220;strong&#8221; year for U.S. stocks, even with the recent pullback.
&#8220;The fallout from the Fed meeting wiped out post-election gains across large swaths of the market, including value stocks and mid-cap and small-cap stocks, though looking back over the entire year, almost every major category is up double-digits so far, across style (value – core – growth) and capitalization (large – mid &#8211; small). For comparison the MSCI All-Cap World ex US Net Index is up just 7.2% year to date. That should tell you how strong of a year 2024 has been for US stocks, even with the recent pullback,&#8221; Varghese said in a note.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Important data is slated to be released on Friday that will help investors to determine the future course of action.
<ul>
<li>On Friday, personal income and spending data along with core and headline PCE index data for November will be released at 8:30 a.m., ET.</li>
<li>Consumer sentiment data for December will be released at 10:00 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) was up 105% in premarket after it inked an IP licensing and mutual exclusivity agreement with Optimi Health Corp., a Canadian psychedelics pharmaceutical manufacturer.</li>
<li>Humacyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) was up 52.31% in premarket after it received FDA approval for SYMVESS, a bioengineered human tissue designed as a universally implantable vascular conduit for arterial injury treatment.</li>
<li>Nike Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) was down 3.37% after issuing <a href="https://www.benzinga.com/24/12/42610441/nikes-new-ceo-says-we-lost-our-obsession-with-sport-as-he-rebukes-old-strategies-on-performance-marketing-isolation-of-wholesalers-aims-to-create-demand">lower revenue guidance</a> and additional gross margin pressure given the higher demand creation expenses.</li>
<li>FedEx Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) was 7.33% higher after it posted stronger-than-expected results for its second quarter. The company also announced that it has decided to pursue a full separation of FedEx Freight through the capital markets, creating a new publicly traded company.</li>
<li>BlackBerry Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) was down 5.03% as it expects fourth-quarter revenue in the range of $126 million to $135 million versus the estimates of $161.49 million.</li>
<li>Winnebago Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) was up 2.04% as analysts expect it to post quarterly earnings at 20 cents per share on revenue of $672.23 million before the opening bell.</li>
<li>Carnival Corporation. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) fell 1.11% as it is expected to report quarterly earnings at 8 cents per share on revenue of $5.93 billion before the opening bell.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures were lower in the early New York session by 2.75% to hover around $68.66 per barrel.
The gold spot index was up by 0.42% to $2,619.24 per ounce. The Dollar Index was down 0.16% to 108.239 level.
Asian markets declined on Friday, as Hong Kong&#8217;s Hang Seng, South Korea&#8217;s Kospi, Japan&#8217;s Nikkei 225, India&#8217;s S&amp;P BSE Sensex, China&#8217;s CSI 300 and Australia&#8217;s ASX 200 index fell. Most European markets were also in the red in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42610958/expecting-up-to-four-fed-rate-cuts-in-2025-says-this-analyst-despite-hawkish-powell-saying-it-was-close-on-the-decision-to-cut-or-not-heres-why">Hawkish Powell Aside, This Analyst Expects 4 Fed Rate Cuts In 2025: Here&#8217;s Why</a></li>
</ul>
Photo courtesy: Wikimedia

US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone'

<h3>Gainers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares moved upwards by 376.8% to $3.19 during Thursday's pre-market session. The market value of their outstanding shares is at $13.7 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock rose 50.2% to $18.4. The company's market cap stands at $2.0 billion. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares increased by 38.56% to $2.12. The market value of their outstanding shares is at $1.7 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock moved upwards by 35.45% to $1.49. The market value of their outstanding shares is at $76.7 million. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) stock rose 33.78% to $9.98. The company's market cap stands at $578.3 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock rose 26.21% to $4.77. The market value of their outstanding shares is at $10.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 35.1% to $0.43 during Thursday's pre-market session. The market value of their outstanding shares is at $5.9 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 26.75% to $2.41. The market value of their outstanding shares is at $10.1 million. </li>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) stock fell 20.01% to $11.2. The company's market cap stands at $681.5 million. </li>
<li>Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) stock decreased by 17.87% to $3.31. The market value of their outstanding shares is at $29.5 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares fell 13.93% to $3.4. The market value of their outstanding shares is at $3.2 million. </li>
<li>Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) stock fell 12.85% to $390.0. The market value of their outstanding shares is at $100.4 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPTH

MRKR

MYNZ

OMER

PLRX

PLRZ

VRTX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Psyence Biomedical shares are trading higher. The company announced it has entered into an IP licensing and mutual exclusivity agreement with Optimi Health Corp.

Biotech

General

Psyence Biomed Patient Screening Underway In Phase IIb Clinical Trial Of Nature Derived Psilocybin; First Patient Expected To Be Randomized Into The Study In January

<h3>Gainers</h3>
<ul>
<li>Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) shares moved upwards by 150.9% to $2.17 during Tuesday's pre-market session. The market value of their outstanding shares is at $195.1 million. </li>
<li>Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) shares rose 136.29% to $2.93. The company's market cap stands at $41.1 million. </li>
<li>Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) shares rose 47.54% to $3.6. The market value of their outstanding shares is at $184.0 million. </li>
<li>NewAmsterdam Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) stock rose 35.74% to $25.14. The market value of their outstanding shares is at $2.3 billion. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 31.88% to $2.73. The market value of their outstanding shares is at $2.3 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) stock increased by 23.87% to $4.41. The company's market cap stands at $41.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock decreased by 73.8% to $2.69 during Tuesday's pre-market session. The company's market cap stands at $22.2 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) stock fell 47.78% to $0.7. The company's market cap stands at $3.1 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) stock decreased by 23.75% to $7.0. The market value of their outstanding shares is at $15.2 billion. </li>
<li>Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) shares declined by 16.87% to $2.42. The market value of their outstanding shares is at $66.5 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares declined by 15.07% to $0.41. The market value of their outstanding shares is at $1.6 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares decreased by 13.64% to $0.95. The company's market cap stands at $16.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIOR

BSGM

CMRX

CPIX

CRDF

CRVO

GELS

ITRM

NAMS

RADX

SXTC

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Under the terms of the agreements, Optimi becomes the exclusive supplier of GMP-certified, nature-derived (non-synthetic) psilocybin extract for Psyence's global drug development and commercialization initiatives for FDA-approved uses in the Palliative Care context.

Contracts

Psyence Biomedical Says Progressed Beyond Previously-Announced Non-Binding LoI And Executed Binding Agreements With Optimi Health

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock rose 110.0% to $4.41 during Monday's pre-market session. The company's market cap stands at $3.6 million. </li>
<li>Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) stock rose 34.05% to $2.48. The market value of their outstanding shares is at $92.8 million. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares increased by 25.17% to $1.84. The company's market cap stands at $148.9 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares increased by 20.82% to $14.39. The company's market cap stands at $118.7 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares moved upwards by 16.71% to $3.77. The market value of their outstanding shares is at $15.9 million. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares increased by 14.22% to $8.94. The company's market cap stands at $470.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) stock decreased by 72.1% to $5.6 during Monday's pre-market session. The company's market cap stands at $200.7 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 51.33% to $1.65. The company's market cap stands at $2.6 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares fell 40.22% to $11.3. The company's market cap stands at $24.5 billion. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares decreased by 20.69% to $3.03. The company's market cap stands at $317.8 million. </li>
<li>Invizyne Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZTC#NASDAQ">IZTC</a>) shares fell 18.36% to $10.81. The market value of their outstanding shares is at $103.0 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 16.46% to $1.98. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIOA

IPHA

IZTC

RVNC

SONN

STRM

<h3>Gainers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 192.4% to $3.07 during Friday's pre-market session. The market value of their outstanding shares is at $4.8 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) shares moved upwards by 25.17% to $1.84. The market value of their outstanding shares is at $28.8 million. </li>
<li>Radiopharm Theranostics Limited - American Depositary Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares increased by 24.5% to $22.0. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares increased by 17.23% to $1.7. The market value of their outstanding shares is at $137.6 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock increased by 14.28% to $2.96. The market value of their outstanding shares is at $3.9 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares rose 14.12% to $0.53. The market value of their outstanding shares is at $21.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock fell 25.3% to $4.63 during Friday's pre-market session. The market value of their outstanding shares is at $2.5 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) stock declined by 18.35% to $8.01. The market value of their outstanding shares is at $161.4 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares fell 14.76% to $0.46. The market value of their outstanding shares is at $3.0 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 14.4% to $2.26. The company's market cap stands at $1.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares declined by 11.62% to $2.74. The market value of their outstanding shares is at $4.3 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares declined by 10.54% to $0.35. The market value of their outstanding shares is at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

CAMP

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

SLXN

SNOA

VRPX

VSEE

<h3>Gainers</h3>
<ul>
<li>Protara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) stock rose 168.9% to $9.52 during Thursday's pre-market session. The company's market cap stands at $196.3 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock moved upwards by 67.86% to $6.53. The market value of their outstanding shares is at $3.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 30.95% to $3.3. The market value of their outstanding shares is at $2.7 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock increased by 16.43% to $14.81. The company's market cap stands at $673.4 million. </li>
<li>Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) stock increased by 15.0% to $6.9. The company's market cap stands at $143.5 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock increased by 13.38% to $11.0. The market value of their outstanding shares is at $90.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) stock fell 32.4% to $0.5 during Thursday's pre-market session. The company's market cap stands at $96.8 million. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) stock declined by 24.26% to $4.81. The company's market cap stands at $13.0 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) stock declined by 12.0% to $1.32. The company's market cap stands at $9.1 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock decreased by 11.91% to $1.85. The market value of their outstanding shares is at $37.4 million. </li>
<li>Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) shares decreased by 11.08% to $3.13. The market value of their outstanding shares is at $27.9 million. </li>
<li>Stevanato Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) stock decreased by 10.5% to $18.0. The company's market cap stands at $4.9 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADVM

BLUE

BRTX

CAPR

Envoy Medical, Inc. - Class A Common Stock

COCH

CYCN

STVN

TARA

Shares of Verint Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) rose sharply in today's pre-market trading after the company reported a year-over-year increase in third-<a href="https://www.benzinga.com/insights/earnings/24/12/42326587/verint-systems-earnings-analysis-q3-recap">quarter financial results</a>.
Verint Systems posted adjusted earnings of 39 cents per share, up from year-ago earnings of 12 cents per share. The company's sales rose to $224.193 million from $218.547 million.
Verint Systems shares jumped 23.2% to $32.00 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) gained 161.5% to $7.01 in pre-market trading after the company announced changes in management including new CFO and CEO appointees.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) rose 72.4% to $4.43 in pre-market trading after dipping more than 10% on Wednesday.</li>
<li>Mawson Infrastructure Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) gained 47.1% to $1.00 in pre-market trading. Mawson Infrastructure Disclosed Australian creditors filed involuntary Chapter 11 petition against the company.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) gained 21.3% to $15.43 in pre-market trading after dipping 23% on Wednesday.</li>
<li>Alset Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEI#NASDAQ">AEI</a>) gained 17.5% to $1.41 in pre-market trading.</li>
<li>BTC Digital Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>) rose 13.9% to $18.24 in pre-market trading after gaining 9% on Wednesday.</li>
<li>Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) gained 13.8% to $119.48 in pre-market trading as the company reported better-than-expected results for its third quarter and issued strong guidance for fiscal 2024. The company also announced the appointment of Winnie Park as CEO and a member of its board of directors, effective Dec. 16, 2024.</li>
<li>ChargePoint Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) climbed 10.6% to $1.35 in pre-market trading after the company reported better-than-expected third-quarter sales results.</li>
<li>BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) gained 10.4% to $1.89 in pre-market trading. BranchOut Food signed a LOI and received $250,000 PO from a leading ingredient distributor.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>bluebird bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) shares tumbled 38.2% to $0.4550 in pre-market trading after the company announced a 1-for-20 reverse stock split.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) declined 26.9% to $0.2924 in pre-market trading after jumping 105% on Wednesday.</li>
<li>Cyclerion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) shares fell 23.2% to $4.88 in pre-market trading after jumping 294% on Wednesday.</li>
<li>Phoenix Motor Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) shares fell 21.4% to $0.2890 in pre-market trading after gaining 13% on Wednesday.</li>
<li>Fusion Fuel Green PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) fell 21.4% to $0.4089 in pre-market trading after gaining over 63% on Wednesday.</li>
<li>SRM Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) fell 20.7% to $0.92 in pre-market trading after climbing 84% on Wednesday.</li>
<li>nCino, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) fell 18.7% to $34.50 in pre-market trading after the company reported third-quarter financial results and issued fourth-quarter revenue guidance below estimates.</li>
<li>CN Energy Group. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>) dipped 16.3% to $0.4273 in pre-market trading after jumping 62% on Wednesday.</li>
<li>SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) shares dipped 14.7% to $24.45 in pre-market trading following third-quarter results.</li>
<li>American Eagle Outfitters, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) fell 14.4% to $17.59 in today's pre-market trading after the company reported a year-over-year decrease in third-quarter sales results. Also, the company said it expects a 4% decrease in fourth-quarter total revenue.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42332881/dow-settles-above-45000-for-first-time-investor-sentiment-improves-fear-greed-index-in-greed-zone">Dow Settles Above 45,000 For First Time As Salesforce, Marvell Surge: Investor Sentiment Improves, Fear Index In &#8216;Greed&#8217; Zone</a></li>
</ul>

BTCT

CHPT

CNEY

FIVE

HTOO

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

NCNO

VRNT

Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket

<ul>
<li>Independent valuation of PsyLabs values Psyence Biomed's stake at approximately $2 million, doubling in value</li>
<li>Debt-for-equity swap with Psyence Group and Newcourt SPAC Sponsor results in strengthened balance sheet, with substantially reduced debt, heading into 2025</li>
<li>Psyence Biomed believes it is on track to regain compliance with all applicable Nasdaq continued listing requirements by year-end</li>
<li>Phase IIb clinical trial progressing as planned; patient screening has commenced</li>
</ul>

Psyence Biomedical Strengthens Financial Position And Advances Psilocybin Clinical Trials In Latest Shareholder Update

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) has successfully obtained an extension from the Nasdaq Hearings Panel, giving the company until December 31, 2024, to meet the exchange's continued listing requirements. The decision, reached after a hearing on October 31, allows the company to remain listed while implementing measures to comply with Nasdaq's rigorous benchmarks.
Psyence Biomed presented a comprehensive plan to address key requirements, including the $1 minimum bid price, a $1 million market value of publicly held shares and $2.5 million in minimum stockholders&#8217; equity. To support these efforts, the company transitioned from The Nasdaq Global Market to The Nasdaq Capital Market as of November 15, 2024.
<h3 class="wp-block-heading">Strategic Steps Toward Compliance</h3>
The company is also enacting a 1-for-75 share consolidation approved during its annual general meeting on November 12. This consolidation aims to achieve compliance with Nasdaq's $1 minimum bid price rule, a common hurdle for smaller-cap stocks.
"We are very pleased to have gained alignment with the Nasdaq Hearings Panel on our plan to regain compliance with all applicable listing requirements," <a href="https://www.globenewswire.com/news-release/2024/11/20/2984341/0/en/Psyence-Biomedical-Announces-Favorable-Result-of-Nasdaq-Listing-Qualifications-Hearing.html">said</a> Dr. Neil Maresky, CEO of Psyence Biomed.
Maresky emphasized the critical importance of maintaining the company's Nasdaq listing: "Having our shares traded on the Nasdaq exchange is critical to raising awareness of our company among healthcare-focused institutional investors. Once these listing requirements are satisfied, we can focus on <a href="https://www.benzinga.com/markets/cannabis/24/09/40884289/psychedelic-biotech-psyence-grows-pipeline-with-trials-and-psilocybin-drug-developer-acquisition">advancing our pipeline</a> of nature-derived psilocybin-based therapeutics as potential treatments for underserved conditions in mental health and addiction where more efficacious options are urgently needed."
The company's strategy aligns with its mission to advance <a href="https://www.benzinga.com/topic/psilocybin-assisted-therapy">psilocybin-based therapeutics</a> targeting mental health and addiction, areas with significant unmet medical needs.&nbsp;
Cover image made with AI

Cannabis

Psychedelics

Psyence Biomedical Secures Extension To Meet Nasdaq Compliance Standards

An announcement from Psyence Biomedical ( ($PBM) ) is now available. Psyence Biomedical has announced significant progress in its Phase IIb clinica...

Psyence Biomedical Advances in Phase IIb Psilocybin Clinical Trial

Psyence Biomedical ( ($PBM) ) has provided an announcement. Psyence Biomedical Ltd. has entered into an IP Licensing and Mutual Exclusivity Agreeme...

Psyence Biomedical Signs Exclusive Licensing Agreement with Optimi Health

16:27 EST Psyence Biomedical (PBM) files to sell 10.9M shares of common stock for holders Published first on TheFly – the ultimate source for real-...

Psyence Biomedical files to sell 10.9M shares of common stock for holders

Psyence Biomedical regains compliance with Nasdaq

Psyence Biomedical (PBM) announced that it has received notice from the Nasdaq Hearings panel that the Company has regained compliance with all app...

Psyence Biomedical regains full compliance with Nasdaq requirements

Psyence Biomedical (PBM) has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares series A commo...

Psyence Biomedical prices 1M shares at $2.00 in private placement

Psyence Biomedical dips 18%, prices $2M offering

Psyence Biomedical ( ($PBM) ) has provided an announcement. Psyence Biomedical Ltd. has regained compliance with all Nasdaq continued listing requi...

Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position

Psyence Biomedical ( ($PBM) ) has shared an update. Psyence Biomedical Ltd. has announced the issuance of a pre-funded common share purchase warran...

Psyence Biomedical Issues Pre-Funded Share Purchase Warrant

An update from Psyence Biomedical ( ($PBM) ) is now available. Psyence Biomedical Ltd. has filed its unaudited interim financial statements for the...

Psyence Biomedical Adjusts Financials for Reverse Stock Split

Press Releases

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

"Power Nickel (TSX.V: PNPN) (OTCQB: PNPNF) Announces Dividend – MIGI, PRFX, PBM, CSDX Stocks Trending Now!"

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Financing

Psyence Biomed Announces $2.0 Million Private Placement

Psyence Biomed Announces Closing of $2.0 Million Private Placement

CSDX

PNPNF

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Alzamend Neuro

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Aptevo Therapeutics

180 Life Sciences

Bio-Path Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Genprex

GRI Bio

GT Biopharma

Lixte Biotechnology Holdings, Inc. - Common Stock

Comments

Psyence Biomedical

Psyence Biomedical (PBM) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL